Differentiation of hepatic stellate cells (HSCs) to extracellular matrix-and growth factor-producing cells supports liver regeneration through promotion of hepatocyte proliferation. We show that the neurotrophin receptor p75 NTR , a tumor necrosis factor receptor superfamily member expressed in HSCs after fibrotic and cirrhotic liver injury in humans, is a regulator of liver repair. In mice, depletion of p75 NTR exacerbated liver pathology and inhibited hepatocyte proliferation in vivo. p75 NTR−/− HSCs failed to differentiate to myofibroblasts and did not support hepatocyte proliferation. Moreover, inhibition of p75 NTR signaling to the small guanosine triphosphatase Rho resulted in impaired HSC differentiation. Our results identify signaling from p75 NTR to Rho as a mechanism for the regulation of HSC differentiation to regeneration-promoting cells that support hepatocyte proliferation in the diseased liver. L iver regeneration driven by hepatocyte proliferation is necessary for tissue repair and survival after acute liver injury, liver transplantation, and chronic hepatic disease, such as liver fibrosis and cirrhosis (1) .
Induction of hepatocyte proliferation depends on cross-talk between hepatocytes and nonparenchymal liver cells, such as hepatic stellate cells (HSCs) (1) . At sites of injury, HSCs differentiate to myofibroblasts and secrete extracellular matrix (ECM) and growth factors that support hepatocyte proliferation (2) . Although HSC differentiation is considered a central process for the induction of liver regeneration, the molecular mechanisms that regulate the transi-tion to repair-supporting cells in the liver remain poorly understood. Expression of p75 NTR is increased in HSCs in the cirrhotic liver in humans and in animal models (3, 4) . p75 NTR is expressed in the nervous system during development or after injury (5) , and it has been primarily studied as a regulator of survival and apoptosis in neurons and glia cells (6) . p75 NTR is also widely expressed in nonneuronal tissues (7) . However, the biological importance of the injury-induced, nonneuronal expression of p75 NTR remains enigmatic.
To address the role of p75 NTR in liver disease in vivo, we crossed mice deficient for p75 NTR with plasminogen-deficient ( plg −/− ) mice (8) that spontaneously develop liver disease (9, 10) . At 5 weeks of age, plg −/− p75 NTR−/− mice were smaller than littermate controls (fig. S1A). plg −/− mice have a median survival time of 6 months (10). By contrast, plg −/− p75 NTR−/− mice had a median survival time of 2.5 months ( Fig. 1A) . plg −/− p75 NTR−/− mice showed prominent liver lesions as early as 10 weeks of age (fig. S1B), with large necrotic areas ( Fig. 1B ) not observed in either wild-type (WT) or 10week-old plg −/− control littermates. Overall, these results suggest that p75 NTR plays a protective role in liver disease.
We hypothesized that p75 NTR might regulate the progression of liver disease via altering the pathophysiological characteristics of HSCs. WT control mice expressed low amounts of p75 NTR , Table 1 . hTERT and human dyskerin peptides sequenced by nanoLC-MS/MS (21) . whereas livers of plg −/− mice expressed more p75 NTR ( Fig. 2A ), which colocalized with the HSC marker desmin ( Fig. 2B ). Gene expression of both a-smooth muscle actin (aSMA) and collagen I (col1a1), which are expressed by HSCs after differentiation to myofibroblasts (11) , was significantly reduced in the livers of plg −/− p75 NTR−/− mice compared with that in the livers of plg −/− mice ( Fig. 2C ). Total numbers of HSCs were similar between plg −/− and plg −/− p75 NTR−/− mice ( fig. S6C ). Examination of fibrin deposition, which is the causative agent for liver disease in the plg −/− mouse (10), showed no differences between plg −/− and plg −/− p75 NTR−/− mice ( fig. S2 ). Overall, these results suggest that p75 NTR regulates liver pathology by inducing HSC activation.
To examine whether p75 NTR might directly regulate HSC differentiation to myofibroblasts, we assessed the ability of primary HSCs isolated from p75 NTR−/− mice to differentiate in vitro. WT HSCs undergo activation within 2 weeks in culture, and p75 NTR expression positively correlates with HSC activation (4). After 3 weeks in culture, WT HSCs exhibited morphologic features of activated myofibroblasts, whereas p75 NTR−/− HSCs were mostly in a quiescent state ( The effects of p75 NTR on HSC differentiation occurred in the absence of exogenous neurotrophin ligands. p75 NTR contributes to several signaling pathways and biological functions, not only following neurotrophin binding but also independently of neurotrophins (5, (13) (14) (15) . In the absence of neurotrophins, p75 NTR or the intracellular domain (ICD) of p75 NTR alone can induce apoptosis (16, 17) and activation of phosphatidylinositol 3-kinase (12) and Rho (18) . Moreover, p75 NTR may act in combination with other receptors, such as Nogo receptor, to mediate biological effects (5, 14, 19) . Neutralization of neurotrophins either by antibody to nerve growth factor (NGF), neurotrophin scavenger Fc-p75 NTR , or brain-derived neurotrophic factor (BDNF) scavenger Fc-TrkB, or inhibition of the other neurotrophin receptor, Trk, had no effect on HSC differentiation ( fig. S5 ). Adenoviral delivery of the ICD of p75 NTR restored differentiation of the p75 NTR−/− HSCs to an extent similar to that of full-length (FL) p75 NTR (Fig. 3B ). Prior studies have shown a 1.5-fold increase in HSC apoptosis after exposure to exogenous NGF (4), which we confirmed ( fig. S6A ). Our differentiation experiments ( Fig. 3 and figs.
S3 to S5 and S7) were done in the absence of exogenous NGF, and WT and p75 NTR−/− HSCs showed no difference in apoptosis ( fig. S6A ), suggesting that apoptosis cannot account for the differences observed in HSC differentiation. HSCs do not show apoptosis in 10-weekold plg −/− mice, whereas apoptosis in the livers of plg −/− p75 NTR−/− mice was exclusive to hepatocytes ( fig. S6B ). These results confirm data from human liver fibrotic disease showing that HSC apoptosis occurs primarily at late stages of liver disease (20) and that differentiated HSCs are resistant to apoptosis (21) . The number of total desmin-positive HSCs was similar in adult WT and p75 NTR−/− mice, suggesting that p75 NTR does not affect the developmental differentiation or the total number of HSCs (fig. S6C ).
The signal transduction mechanisms that promote and control HSC differentiation into myofibroblasts remain elusive. Rho is implicated in regulating myofibroblast morphology through reorganization of the actin cytoskeleton (22) . A signaling relationship between p75 NTR and Rho is well documented in the nervous system, where p75 NTR -mediated Rho signaling is involved in the regulation of neurite outgrowth (23) . Because either p75 NTR in the absence of ligand or the ICD of p75 NTR alone can activate Rho through a direct interaction (18) and because Rho is involved in promoting the myofibroblastic state of HSCs (22) , we examined whether p75 NTR promoted HSC activation through Rho. Unlike in WT HSCs, expression of phospho-cofilin, a marker for Rho activation (24) , was undetectable in p75 NTR−/− HSCs (Fig. 3C ). Adenoviral delivery of constitutively activated Rho (25) restored differentiation in p75 NTR−/− HSCs (Fig. 3D) . WT HSCs treated with TAT-Pep5, which is a cell-permeable peptide inhibitor that specifically blocks the activation of Rho through p75 NTR (23), showed undifferentiated morphology (Fig. 3E) , reduced immunostaining of phospho-cofilin ( fig. S7A ), and decreased gene expression of col1a1 and TGFb-1 ( fig. S7B ), similar to the features of p75 NTR−/− HSCs. Taken together, these results suggest that p75 NTR signaling through Rho promotes HSC differentiation to myofibroblasts.
Because cross-talk of HSCs with hepatocytes drives hepatocyte proliferation and liver repair (1, 2, 26), we examined whether p75 NTR could regulate hepatocyte proliferation. plg −/− mice showed an increased number of proliferating hepatocytes [126.6 ± 3.9 (SEM), Fig. 4A ] when compared with WT mice [95.2 ± 3.7 (SEM)], suggestive of the regenerative response in the liver after injury. By contrast, plg −/− p75 NTR−/− mice displayed significantly decreased cell proliferation [74.2 ± 9.1 (SEM)] compared with plg −/− mice ( Fig. 4A , P < 0.001). One of the key mediators in promoting hepatocyte proliferation is hepatocyte growth factor (HGF) (1) . Wholeliver homogenates from plg −/− p75 NTR−/− mice showed only one-third of the amount of HGF protein detected in plg −/− livers (Fig. 4B ). HSCs are a major source of HGF in the liver (27, 28) ; thus, the reduction in HGF in the plg −/− p75 NTR−/− mouse is in accordance with the defective HSC activation observed after genetic loss of p75 NTR both in vivo ( Fig. 2C ) and in vitro (Fig. 3) . In co-culture (26) , hepatocytes in culture with p75 NTR−/− HSCs exhibited a 30% decrease in proliferation compared with those incubated with WT HSCs (Fig. 4C , P < 0.05). Proliferation was largely restored when HGF was added to the culture medium ( Fig. 4C ). Taken together, these results suggest that p75 NTR expression by HSCs is necessary for their differentiation to repairsupporting, HGF-secreting cells, which in turn can promote hepatocyte proliferation.
HSC differentiation is a hallmark of fibrotic liver disease of different etiologies, such as hepatitis and chronic alcohol consumption (20) . Initiation of HSC differentiation results in secretion of HGF and synthesis of ECM, which are critical mediators for the restoration of normal liver structure, hepatocyte proliferation, and liver regeneration (1). However, perpetuation of HSC activation to a myofibroblastic state leads to excessive collagen and ECM deposition, which results in liver fibrosis. Therefore, sustained differentiation of HSCs is considered a target for the treatment of liver fibrosis (11) . At late stages of liver disease, resolution of fibrosis depends on HSC apoptosis (20) . Our study showed that p75 NTR induces HSC differentiation and demonstrated that the mild in vitro effect of NGF on HSC apoptosis (4, 29) is mediated by p75 NTR . These results suggest that in liver injury p75 NTR might function both as a regulator of HSC differentiation and, depending on the bioavailability of neurotrophins, might also participate together with other apoptotic mediators in orchestrating the resolution of fibrosis. Identification of p75 NTR as a molecular link between HSC activation and hepatocyte proliferation could provide a therapeutic target for manipulating the stages of HSC activation during the progression of chronic liver disease. Fig. 4 . p75 NTR -dependent promotion of hepatocyte proliferation through regulation of HGF secretion by HSCs. (A) Liver cell proliferation in plg −/− p75 NTR+/+ and plg −/− p75 NTR−/− mice. Ten-week-old mice were injected intraperitoneally with bromodeoxyuridine (BrdU) (100 mg/kg) daily for 3 days. Proliferating cells were visualized by immunochemical detection of BrdU. Liver cell proliferation was quantified by counting the number of BrdU+ cells per field (field corresponds to 1.5 mm 2 ) (top right). Graph represents mean ± SEM (n = 5 per genotype, *P < 0.001 by unpaired Student's t test). Scale bar, 198 mm. (B) HGF in the livers of plg −/− and plg −/− p75 NTR−/− mice as quantified by enzymelinked immunosorbent assay. Graph represents mean ± SEM (n = 8 for plg −/− and n = 5 for plg −/− p75 NTR−/− , *P < 0.0001 by unpaired Student's t test). (C) Culture of primary hepatocytes with WT and p75 NTR−/− HSCs. Hepatocytes were plated in the bottom of the well and incubated with HSCs grown on inserts placed within the well. Hepatocytes were cultured with WT or p75 NTR−/− HSCs (day 7 to 21, passage 2 to 4), with or without HGF (50 ng/ml). After 2 days, hepatocyte proliferation was assessed by [ 3 H]thymidine incorporation (right). All data are mean ± SEM from four independent experiments performed in duplicates (*P < 0.05 and ns, not significant, by one-way ANOVA).
